Humanitarian Use Device (HUD)

Humanitarian Use Device (HUD) is a U.S. Food and Drug Administration (FDA) designation for a medical device intended to treat or diagnose a disease or condition that affects, or is manifested in, not more than 8,000 individuals in the United States per year. HUD designation is the gateway to the Humanitarian Device Exemption (HDE) — a marketing-authorization pathway, distinct from a standard Premarket Approval (PMA), that lets a sponsor bring a device to market by demonstrating probable benefit rather than the full “reasonable assurance of effectiveness” a PMA requires. The pathway is defined in the Federal Food, Drug, and Cosmetic Act (FD&C Act) Section 520(m) and implemented in 21 CFR Part 814, Subpart H.

The 8,000-patient threshold

A device qualifies for HUD designation only if the disease or condition it addresses affects or is manifested in no more than 8,000 people in the U.S. per year. For a diagnostic device, FDA applies the threshold to the number of individuals who would be subject to diagnosis by the device, not the prevalence of the underlying disease itself — a distinction sponsors sometimes miss when drafting a designation request.

This threshold was raised from “fewer than 4,000” to “not more than 8,000” by Section 3052 of the 21st Century Cures Act, effective December 13, 2016, and formalized through a June 2017 Federal Register technical amendment. Any pre-2016 reference to a 4,000-patient cutoff is describing the superseded standard. (Source: FDA’s HUD Designation Program page; Federal Register technical amendment, 2017-11816.)

Two-step pathway: designation, then exemption application

Getting an HUD to market is a two-step regulatory process, not one submission:

1. HUD designation request — filed with FDA’s Office of Orphan Products Development (OOPD), the same office that administers orphan drug designation. The sponsor documents the epidemiology supporting the ≤8,000-patient estimate.
2. HDE application — once designation is granted, the sponsor submits a Humanitarian Device Exemption application to the relevant premarket review center (typically CDRH for devices, CBER for certain biologic-device combinations), containing device description, manufacturing information, labeling, and the probable-benefit evidence described below.

Only after both steps clear does FDA authorize marketing under the HDE. (Source: FDA, “Getting a Humanitarian Use Device to Market”.)

The HDE approval standard: “probable benefit,” not “reasonable assurance of effectiveness”

This is the operational core of the designation. A standard PMA requires a sponsor to demonstrate a reasonable assurance of both safety and effectiveness, ordinarily through adequately powered clinical trials — infeasible for a condition with, by definition, a tiny eligible population. An HDE instead requires FDA to find that:

• the device will not expose patients to an unreasonable or significant risk of illness or injury; and
• the probable benefit to health from using the device outweighs the risk of injury or illness, taking into account the risks and benefits of currently available alternatives.

The law explicitly exempts HDE devices from the effectiveness-demonstration requirement that applies to a PMA — sponsors show probable benefit, not proven effectiveness. This is the trade-off that makes the pathway viable for ultra-rare conditions: less evidence is required, but the device also isn’t held to have proven it works the way an approved PMA device has.

IRB oversight and the central-IRB option

An approved HUD may only be used at a healthcare facility with an Institutional Review Board (IRB) that has reviewed and approved its use — for most HDE uses this replicates the same IRB gate that governs an investigational device or clinical protocol review at that site, even though the device itself is FDA-authorized rather than “investigational.” The 21st Century Cures Act also opened the door to using a central (single) IRB for HDE oversight instead of requiring separate local-IRB review at every site of use, aligning HDE oversight with the broader move toward central IRB models in multi-site device and drug research.

Profit restrictions and the Annual Distribution Number (ADN)

Because an HDE device hasn’t demonstrated effectiveness the way a PMA device has, the FD&C Act historically barred selling an HDE device for profit, with narrow exceptions. The 21st Century Cures Act relaxed this: a sponsor may now request FDA authorization to sell an HDE device for profit if the device is intended for a disease or condition that either (a) affects pediatric patients (defined for this purpose as under 22 years of age) or (b) does not occur in pediatric patients at all. FDA evaluates each profit request rather than granting it automatically.

Separately, every HDE carries an Annual Distribution Number (ADN) — the number of devices reasonably needed to treat, diagnose, or cure a population of up to 8,000 individuals, calculated from the number of devices needed per patient per year. The ADN caps how many units the sponsor may distribute annually under that HDE; it was redefined, not eliminated, by the 2016 threshold change.

Cost: the MDUFA user-fee exemption

Unlike a PMA — whose FY2026 standard FDA user fee runs in the hundreds of thousands of dollars — an HDE application is exempt from Medical Device User Fee Amendments (MDUFA) review fees, aside from the annual facility establishment fee that applies to device manufacturers generally. This fee exemption, alongside the reduced evidentiary burden, is one of the two concrete cost levers the pathway offers a resource-constrained sponsor such as a university spinout.

HUD/HDE compared to adjacent designations

• Orphan drug designation — the drug/biologic equivalent, administered by the same FDA Office of Orphan Products Development, but the population ceiling is up to 200,000 U.S. patients — 25x the HUD ceiling — reflecting how much smaller the addressable population for a rare-disease device typically has to be to qualify.
• Investigational Device Exemption (IDE) — governs a device that is still under clinical investigation and not yet legally marketed; an HDE, by contrast, is itself a marketing authorization, not a permission to conduct a study. A device may pass through IDE-governed investigation on its way to an HDE (or PMA) submission.
• Premarket Approval (PMA) — the standard, non-exempted device-approval pathway, requiring proof of effectiveness. HDE is best understood as a narrower, lower-evidentiary-burden substitute for PMA that is only available below the 8,000-patient ceiling.
• 510(k) clearance — a substantial-equivalence pathway for devices similar to an already-legally-marketed predicate device; not an option for most genuinely novel rare-disease devices, which typically lack a predicate.

Why it matters for research administrators and technology transfer offices

For a university medical-device spinout, the HUD/HDE pathway is frequently the only commercially realistic route to market for a device addressing an ultra-rare condition — a population too small to recruit an adequately powered PMA effectiveness trial against, and too small to interest most venture investors under a standard PMA timeline and cost. Understanding HDE early changes how a technology transfer office structures the underlying invention disclosure, licensing terms, and industry-partnership agreements:

• Licensing and profit terms should account for the HDE profit restriction and the FDA-authorization step required before a licensee can sell the device for profit — a materially different risk/return profile than a standard PMA-track license.
• Clinical development planning shifts from powering an effectiveness trial toward assembling the probable-benefit evidence package (which can draw on smaller studies, registries, or literature) OOPD and the review center expect to see.
• Manufacturing and quality-system obligations under HDE approval are not relaxed alongside the effectiveness standard — an approved HUD is still subject to the FDA Quality Management System Regulation and postmarket reporting requirements that apply to any approved device.
• IRB and site-use planning needs to be built into any clinical collaboration or distribution agreement from the start, since use is legally gated to IRB-approved sites.

The pathway sits squarely at the intersection of clinical-research regulatory compliance and technology-transfer commercialization strategy — a research administrator advising a device inventor benefits from understanding both halves, not just the FDA regulatory mechanics or only the licensing economics in isolation.

Worked examples

The following are hypothetical, illustrative scenarios describing how the threshold and process apply — not descriptions of any specific real device, company, or institution.

• A university spinout develops an implantable device for a rare pediatric metabolic disorder estimated to affect roughly 3,000 children in the U.S. annually. Because that population sits under the 8,000-patient ceiling, the inventor’s technology transfer office files an HUD designation request with OOPD before finalizing licensing terms, then supports an HDE application to CDRH built around a probable-benefit case rather than a full randomized effectiveness trial — a materially faster and cheaper route than a standard PMA track would have been.
• A diagnostic imaging platform is designed to identify a rare genetic retinal disorder. Because HUD eligibility for a diagnostic device turns on how many people would be subject to the test — not how many people have the underlying disease — the sponsor documents projected annual test volume, not disease prevalence, in its designation request.

Counter-example

A device intended to treat type 2 diabetes — a condition affecting tens of millions of Americans — cannot qualify for HUD designation no matter how innovative the device is. The population ceiling is a hard eligibility gate tied to disease incidence, not a measure of unmet clinical need or technical novelty; a device for a common condition must instead pursue a standard PMA, De Novo, or 510(k) pathway regardless of how underserved a particular sub-population might be.

Frequently asked questions

Is an HDE the same as FDA “approval”?

An HDE is technically an approval (FDA “approves” the HDE application), but it is explicitly not equivalent to a PMA approval — the underlying evidentiary standard (probable benefit vs. demonstrated effectiveness) is different, and that distinction should be reflected accurately in any labeling, marketing, or licensing materials referencing HDE status.

Can an HDE-approved device be used outside an IRB-approved site?

No. Use is legally restricted to facilities with an IRB that has reviewed and approved the device’s use at that site, though a central IRB can now satisfy this requirement across multiple sites rather than requiring separate local review at each one.

How is HUD different from an Investigational Device Exemption (IDE)?

An IDE authorizes a device to be used in a clinical investigation before it is legally marketed. An HDE is a marketing authorization for a device that has already completed FDA review — the two operate at different stages of a device’s regulatory lifecycle, and a device intended for the HDE pathway may still need IDE-governed study data to support its probable-benefit case.

Does HUD designation apply to drugs?

No — HUD/HDE is a medical-device-specific pathway. The equivalent designation for drugs and biologics is orphan drug designation, administered by the same FDA Office of Orphan Products Development but under a much higher population ceiling (up to 200,000 U.S. patients).